ANAKIN: A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutaneous administration of anakinra in patients with cystic fibrosis.
The primary objective of the study is to evaluate efficacy of treatment with anakinra in subjects with cystic fibrosis (CF) by means of lung clearance index (LCI) in adults and in addition in adolescents if effective in adults.
Study details
Study-ID: NCT03925194, 2023-510376-31-00
Study-ID: NCT03925194, 2023-510376-31-00
DZL Disease Area: CFBE
DZL Disease Area: CFBE
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL Investigator Initiated Trial, DZL discovery-based, DZL on steering board
DZL Role: DZL recruiting center, DZL Investigator Initiated Trial, DZL discovery-based, DZL on steering board
Funding: DZL
Funding: DZL
DZL Participating Sites: TLRC, BIH / Charité - Associated Partner
DZL Participating Sites: TLRC, BIH / Charité - Associated Partner
Start Date: 01.09.2019
Completion Date: 01.01.2027
Status: Recruiting
Status: Recruiting
DZL recruiting center, DZL Investigator Initiated Trial, DZL discovery-based, DZL on steering board
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
